Clinical Trials on Diabetes Insipidus in Norway

Total 397 results

Novo Nordisk A/S

Completed

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-5)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Poland, Denmark, France, Netherlands, Austria, Spain, Finland, Argentina, India, Russian Federation, United Kingdom, Slovakia, Brazil, Norway, Former Serbia and Montenegro, South Africa, Philippines
Intarcia Therapeutics

Completed

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States
Sanofi

Completed

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (LanScape)

Diabetes Mellitus, Type 2

Australia, United Kingdom
Eli Lilly and Company

Recruiting

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)

Type 2 Diabetes

United States, Taiwan, China, Mexico, Germany, Poland
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)

Type 2 Diabetes | T2D

United States, Mexico, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes (BEGIN™)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, United Kingdom, Belgium, Norway, Germany, Greece
Sanofi

Completed

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR)

Type 2 Diabetes Mellitus

United States, Australia, Spain, Korea, Republic of, Hungary, Mexico, Italy, Poland, Argentina, Canada, Colombia, France, Germany, Japan, Peru, Romania, Sweden, United Kingdom
Inventiva Pharma

Active, not recruiting

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

Diabetes Mellitus, Type 2 | NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Netherlands, United Kingdom
Pfizer

Terminated

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

Diabetes Mellitus, Type 1

Denmark, Spain, Sweden, United States, Belgium, Austria, France, Portugal, Ireland, United Kingdom, Finland, Netherlands, Norway
Takeda

Terminated

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Argentina, Mexico, Chile, Peru
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM)

Type 2 Diabetes Mellitus

United States, Bulgaria, Hungary, Slovakia
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Puerto Rico, Mexico
Pfizer
Sanofi

Completed

US Inhaled Insulin Dose Titration Study

Diabetes Mellitus, Type 2

United States
Hoffmann-La Roche

Completed

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

Diabetes

United States, Panama, Mexico, Canada, Estonia, Lithuania, Bulgaria, Romania, Latvia, Puerto Rico, United Kingdom
AstraZeneca
Bristol-Myers Squibb

Completed

52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period

Type 2 Diabetes

Korea, Republic of, Russian Federation, United Kingdom, Vietnam, Germany, Hungary, Finland, Norway, Netherlands, Slovakia, India
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Poland, Russian Federation, United Kingdom, Denmark, Finland, Sweden
Novo Nordisk A/S

Completed

Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Spain, Denmark, Austria, Belgium, Serbia, Germany, Slovenia, Canada, France, Finland, Former Serbia and Montenegro, Czech Republic, Norway
Takeda

Terminated

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Eli Lilly and Company

Recruiting

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)

Type 2 Diabetes

United States, China, Japan, Argentina, Puerto Rico, Mexico
Eli Lilly and Company
OPKO Health, Inc.

Completed

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Takeda

Terminated

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Diabetes

United States, Peru, Argentina
Intarcia Therapeutics

Completed

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Type 2 Diabetes

United States
Sanofi

Completed

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States, Chile, Czech Republic, Denmark, France, Germany, Hungary, Lithuania, Mexico, Poland, Romania, Slovakia, Sweden
GlaxoSmithKline

Withdrawn

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

United States
Lexicon Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy

Type 2 Diabetes Mellitus

United States, Canada, Mexico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
Novo Nordisk A/S

Completed

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes (LEAD-6)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Denmark, Sweden, Austria, Germany, Macedonia, The Former Yugoslav Republic of, Slovenia, France, Switzerland, Norway, Spain, Ireland, Finland, Romania
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)

Type 2 Diabetes

United States, Puerto Rico, Spain, Germany, Argentina, Brazil, Turkey, Hungary, Italy, Russian Federation, Slovakia, Belgium, Czechia, Greece, Mexico, Romania
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

Type 2 Diabetes Mellitus

Russian Federation, United States, Puerto Rico, Australia, Taiwan, Israel, Spain, Canada, Greece, Argentina, Poland, Romania, Mexico, Slovakia, Brazil
Novo Nordisk A/S

Completed

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Israel, Poland, United Kingdom, Denmark, Spain, France, Austria, Norway, Russian Federation, Canada, Croatia, Argentina, South Africa, Australia, Ireland, Brazil, Finland
Novo Nordisk A/S

Completed

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Spain, Denmark, Austria, Belgium, Serbia, Germany, Canada, France, Finland, Norway, Czech Republic
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone (GETGOAL-P)

Diabetes Mellitus Type 2

United States, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico, Romania, Turkey
Eli Lilly and Company

Active, not recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Type 2 Diabetes

United States, Spain, Taiwan, Japan, Poland, Argentina, Hungary, Puerto Rico, Korea, Republic of, Slovakia
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Novo Nordisk A/S

Completed

Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1 | Delivery Systems

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Multicenter, Double-blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Erectile Dysfunction

United States, Canada
Eli Lilly and Company

Completed

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)

Diabetes | Type 2 Diabetes

United States, China, Germany, Mexico, Brazil, Canada, Japan, Korea, Republic of, Puerto Rico, Czechia, Greece
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)

Type 2 Diabetes

United States, Puerto Rico, Australia, United Kingdom, Mexico, Argentina, Brazil, Israel, Canada
Novo Nordisk A/S

Completed

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1

Israel, United Kingdom, France, Netherlands, Spain, Finland, Malaysia, Norway, Italy, Germany, Poland, Romania, Portugal, Ireland, Croatia, Greece
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms (DUAL™ VI)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Canada, Austria, Hungary, Serbia, Russian Federation, Bulgaria, Czechia
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Eli Lilly and Company

Recruiting

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Argentina, Puerto Rico
AstraZeneca
Bristol-Myers Squibb

Completed

Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin (GENERATION)

Type 2 Diabetes Mellitus

Sweden, Italy, United Kingdom, Finland, Norway, Mexico, Austria, Denmark, Germany, Hungary, Greece, France, Spain
Novo Nordisk A/S

Completed

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes (PIONEER PLUS)

Diabetes Mellitus, Type 2

United States, India, Taiwan, Poland, Australia, Estonia, Hungary, Germany, Slovakia, Canada, Croatia, Bulgaria, Puerto Rico, Czechia, Slovenia
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
Novo Nordisk A/S

Completed

Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes (EFFICACY)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico, Argentina, Thailand, India, Korea, Republic of
AstraZeneca

Terminated

GALLANT 6 Tesaglitazar vs. Pioglitazone

Diabetes Mellitus, Type 2

United Kingdom, Finland, Norway, Canada, Mexico, Argentina, Brazil, United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Nutritional and Metabolic Diseases

United Kingdom, Germany, Belgium, Poland, India, Finland, Sweden, Netherlands, Russian Federation, Norway, Denmark

Clinical Trials on Diabetes Insipidus in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations